摘要
目的 比较点突变p5 3及其抗原肽重组痘苗病毒诱导的抗瘤免疫反应 ,为重组抗原疫苗用于肿瘤免疫治疗提供实验依据。方法 以人 135位Cys→Tyr点突变 p5 3为肿瘤相关抗原模型 ,观察以表达该点突变 p5 3蛋白的重组痘苗病毒rVV p5 3FL与表达包含该点突变抗原肽 p5 312 5 14 5的重组痘苗病毒rVV p5 3M 所诱导的CTL及对荷瘤Balb/c小鼠的免疫保护和治疗作用。结果 rVV p5 3FL和rVV p5 3M 均能诱导以CD8+T细胞为主的特异性CTL。用rVV p5 3FL与rVV p5 3M 免疫小鼠后 ,接种致死剂量的P815 mp5 3细胞 ,能保护部分小鼠免遭致死剂量肿瘤细胞的攻击。小鼠接种致死剂量的肿瘤细胞后 ,以rVV p5 3FL与rVV p5 3M 治疗荷瘤小鼠 ,可使小鼠平均存活时间显著延长。两种疫苗的抗瘤效应无明显区别。结论 来源于突变p5 3的抗原肽重组疫苗 。
Aim To explore antitumor responses induced by recombinant vaccinia viruses expressing a point mutant p53 (rVVp53 FL )and its antigenic peptide rVVp53 M). Methods P815 mastocytoma transduced with a 135 Cys to Tyr point mutation p53 was used as an experimental tumor (P815mp53) and the p53 protein as the model of tumor associated antigen. rVVp53 FL and rVVp53 M were used as tumor vaccine to investigate their induction of CTL and antitumor immunity. Results Immunizing Balb/c mice with rVVp53 FL and rVVp53 M could induce specific CTLs, which specifically lysed P815mp53 cells. After the immunized mice were challenged with a lethal dose of P815mp53, a part of the mice survived. The mice bearing tumor was treated with rVVp53 FL and rVVp53 M, which could significantly prolong the mice′ s survival time. Antitumor response induced by rVVp53 M was comparable to that by rVVp53 FL . Conclusion antigenic peptide derived from mutant p53 protein may replace the protein as vaccine for antitumor immunotherapy.
出处
《细胞与分子免疫学杂志》
CSCD
2000年第3期248-251,263,共5页
Chinese Journal of Cellular and Molecular Immunology
